Oculis announces positive Phase 2b results for dry eye disease treatment
Oculis Holding AG has reported positive topline results from its Phase 2b RELIEF trial evaluating licaminlimab, an anti-TNFα eye drop, for dry eye disease, according to a company press release.
The study demonstrated significant improvements in multiple efficacy endpoints, particularly in patients with a TNFR1 genetic biomarker. Licaminlimab showed a rapid effect on corneal inflammation and was well tolerated.
Oculis plans to advance to Phase 3 trials following discussions with the FDA.
“The precision medicine approach with licaminlimab could be a groundbreaking paradigm shift in ophthalmology and the treatment of DED,” said Eric Donnenfeld, MD, Clinical Professor of Ophthalmology at New York University and Chair of Oculis’ Cornea Scientific Advisory Board, in the press release. “The current approach of ‘trial and error’ and our inability to predict response for this highly heterogenous population leads to a low level of patient satisfaction. To my knowledge, Licaminlimab is the first dry eye disease medication to demonstrate in a clinical trial a predictive treatment effect in patients with a common genetic biomarker to potentially solve this problem.”
The full press release can be found here.
